Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

British Journal of Psychiatry

Volumn 187, Issue AUG., 2005, Pages 131-136

  Fleischhacker, W Wolfgang ^a   Rabinowitz, Jonathan ^b   Kemmler, Georg ^a   Eerdekens, Marielle ^c   Mehnert, Angelika ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b BAR ILAN UNIVERSITY   (Israel)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SHORT FORM 36; SOCIAL INTERACTION; WELLBEING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ANXIETY; DEPRESSION; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF ASSESSMENT (PSYCHOLOGY); TIME FACTORS; TREATMENT OUTCOME;

EID: 23744446812     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.187.2.131     Document Type: Article

References (27)

1. Aksaray, G., Oflu, S., Kaptanoglu, C., et al (2002) Neurocognitive deficits and quality of life in outpatients with schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry, 26, 1217-1219.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Washington, DC: APA.
3. Bengtsson-Tops, A. & Hansson, L. (1999) Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics. European Psychiatry, 14, 256-263.
4. Cohen, J. (1976) Statistical Power Analysis for the Behavioral Sciences (2nd edn). Hillsdale, NJ: Erlbaum.
5. Cook, P. E., Goldberg, J. O. & Van Lieshout, R. J. (2002) Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting. Canadian Journal of Psychiatry, 47, 870-874.
6. Csernansky, J. G., Mahmoud, R. & Brenner, R. (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346, 16-22.
7. Doyle, M., Flanagan, S., Browne, S., et al (1999) Subjective and external assessment of quality of life in schizophrenia: relationship to insight. Acta Psychiatrica Scandinavica, 99, 466-472.
8. Eerdekens, M., Van Hove, I., Remmerie, B., et al (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research, 70, 91-100.
9. Fleischhacker, W.W., Eerdekens, M., Karcher, K., et al (2003) Treatment of schizophrenia with long-acting risperidone: a 12-month evaluation of the first long-acting injectable atypical antipsychotic. Journal of Clinical Psychiatry, 64, 1250-1257.
10. Guy, W. (2000) Clinical Global Impression (CGI). In Handbook of Psychiatric Measures (ed. A. J. Rush), pp. 100-102. Washington, DC: American Psychiatric Association.
11. Hamilton, S. H., Edgell, E. T., Revicki, D. A., et al (2000) Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. International Clinical Psychopharmacology, 15, 245-255.
12. Kane, J. M. (1999) Pharmacologic treatment of schizophrenia. Biological Psychiatry, 46, 1396-1408.
13. Karow, A. & Naber, D. (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berlin), 162, 3-10.
14. Kay, S. R. & Singh, M. M. (1989) The positive-negative distinction in drug-free schizophrenic patients: stability, response to neuroleptics, and prognostic significance. Archives of General Psychiatry, 46, 711-718.
15. Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
16. Lehman, A. F., Ward, N. C. & Linn, L. S. (1982) Chronic mental patients: the quality of life issue. American Journal of Psychiatry, 139, 1271-1276.
17. Leucht, S., Barnes, T. R., Kissling, W., et al (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry, 160, 1209-1222.
18. Marder, S. R., Davis, J. M. & Chouinard, G. (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry, 58, 538-546.
19. Nasrallah, H., Duchesne, I., Mehnert, A., et al (2004) Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Journal of Clinical Psychiatry, 65, 531-536 (erratum: 65, 1150).
20. Russo, J., Trujillo, C. A., Wingerson, D., et al (1998) The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Medical Care, 36, 752-756.
21. Sartorius, N., Fleischhacker, W. W., Gjerris, A., et al (2002) The usefulness and use of second generation antipsychotic medications. Current Opinion in Psychiatry, 15 (suppl. I), S1-S51.
22. Sartorius, N., Fleischhacker, W. W., Gjerris, A., et al (2003) The usefulness and use of second generation antipsychotic medications - an update. Current Opinion in Psychiatry, 16 (suppl. I), S1-S44.
23. Steiger, J. H. (1989) EzPATH: Causal Modeling. Evanston, IL: SYSTAT Inc.
24. Tunis, S. L., Croghan, T. W., Heilman, D. K., et al (1999) Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care, 37, 678-691.
25. Ware, J. E. (2003) SF-36. http://www.sf.-36.org/ nbscalc/index.shtml
26. Ware, J. E., Snow, K., Kosinksi, M., et al (1993) SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: Health Institute.
27. Ware, J. E., Kosinski, M., Gandek, B., et al (1998) The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. Journal of Clinical Epidemiology, 51, 1159-1165.